Real-world treatment patterns and clinical outcomes with tucatinib-based therapy in patients with HER2-positive metastatic breast cancer: analyses of two nationwide administrative health claims databases
International Journal of Clinical Oncology · 2025
DOI: 10.1007/s10147-025-02800-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Carey Anders und 8 weiteren Autor:innen. Beteiligte Einrichtung: Duke Cancer Institute (Breast Clinic), Durham, NC, USA. carey.anders@duke.edu. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Quinazolines, Pyridines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Purpose
To describe real-world characteristics and clinical outcomes among patients with HER2+ MBC receiving tucatinib-based treatments.
Methods
This retrospective study included patients diagnosed with HER2+ MBC between January 2017 and December 2022 from two administrative health claims databases, Merative TM MarketScan ® and the Komodo Healthcare Map ™ . Patient characteristics were captured at baseline (≤ 6 months prior to tucatinib initiation). Outcomes were assessed starting from tucatinib-based treatment initiation and included real-world time to discontinuation (rwTTD) and treatment persistence.
Results
There were 150 patients in MarketScan ® who received tucatinib-based therapy: median (IQR) prior lines of therapy (LOT) was 2 (2–4) and 110 patients (73.3%) had brain metastases. 436 patients in Komodo ™ received tucatinib-based therapy: median (IQR) prior LOTs were 2 (1–3), and 307 (70.4%) had brain metastases. Median (95% CI) rwTTD was 7.4 (5.0–13.1) months in MarketScan ® (median follow-up 9.7 months) and 9.0 (7.4–9.8) months in Komodo ™ (median follow-up 10.3 months). In patients who received tucatinib in combination with trastuzumab and capecitabine immediately following trastuzumab deruxtecan (T-DXd) and after ≥ 2 prior HER2-directed therapies (MarketScan ® : n = 26, median prior LOT 4; Komodo: n = 34, median prior LOT 3), median (95% CI) rwTTD was 5.5 (3.4–not reached [NR]) months in MarketScan ® and 4.8 (3.2–NR) months in Komodo.
Conclusion
These results reinforce the real-world effectiveness of tucatinib in patients with HER2+ MBC, including patients with prior T-DXd treatment. Further research is needed to determine the optimal treatment sequencing for patients with HER2+ MBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Duke Cancer Institute (Breast Clinic), Durham, NC, USA. carey.anders@duke.edu.
- Pfizer Inc, South San Francisco, CA, USA.
- Genesis Research, Hoboken, NJ, USA.
- Medical Center (Hematology and Oncology), University of Vermont, Burlington, VT, USA.
- Winship Cancer Institute, Atlanta, GA, USA.
Förderung
- Pfizer
Zitieren
APA
Anders, C., Neuberger, E., Schwartz, N. R. M., Bartley, K., Wang, S., Liu, Y., Pittner, B. T., Kaufman, P. A., & Meisel, J. (2025). Real-world treatment patterns and clinical outcomes with tucatinib-based therapy in patients with HER2-positive metastatic breast cancer: analyses of two nationwide administrative health claims databases. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-025-02800-7
Vancouver
Anders C, Neuberger E, Schwartz NRM, Bartley K, Wang S, Liu Y, et al. Real-world treatment patterns and clinical outcomes with tucatinib-based therapy in patients with HER2-positive metastatic breast cancer: analyses of two nationwide administrative health claims databases. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-025-02800-7
BibTeX
@article{Anders2025,
author = {Anders, Carey and Neuberger, Edward and Schwartz, Naomi R M and Bartley, Karen and Wang, Shu and Liu, Yutong and Pittner, Brian T and Kaufman, Peter A and Meisel, Jane},
title = {Real-world treatment patterns and clinical outcomes with tucatinib-based therapy in patients with HER2-positive metastatic breast cancer: analyses of two nationwide administrative health claims databases},
journal = {International Journal of Clinical Oncology},
year = {2025},
doi = {10.1007/s10147-025-02800-7}
}
EUVIMED